{"id":"pf-07329640","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{"Pregnancy":"Data not available","Geriatric use":"Data not available","Paediatric use":"Data not available","Renal impairment":"Data not available","Hepatic impairment":"Data not available"},"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT06448364"],"_pubmed":{"count":0,"papers":[]},"_rxnorm":{"forms":[]},"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2020","type":"neutral","milestone":"Phase 1 trial initiated in advanced/metastatic solid tumors","regulator":"none","description":"Pfizer initiated Phase 1 evaluation of PF-07329640 as monotherapy in patients with advanced or metastatic solid tumors, including NSCLC."},{"date":"2023","type":"negative","milestone":"Phase 1 trial terminated","regulator":"none","description":"Phase 1 study was terminated early with only 4 patients enrolled, indicating insufficient efficacy or safety signals to warrant further development."}],"aiSummary":"PF-07329640 is a Pfizer-developed oncology candidate that was discontinued during Phase 1 clinical development. The compound was being evaluated as a monotherapy in patients with advanced or metastatic solid tumors, including non-small cell lung cancer. No FDA label, mechanism of action details, or molecular target information is publicly available in the source data, limiting comprehensive characterization. The Phase 1 trial was terminated early with minimal enrollment (N=4), suggesting either safety concerns, lack of efficacy signals, or strategic portfolio decisions by Pfizer. Without published clinical data, peer-reviewed literature, or regulatory filings, the drug's commercial potential and scientific differentiation cannot be assessed. The discontinuation indicates this candidate did not advance to later-stage development.","brandName":"PF-07329640","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"Data not available","novelty":"Data not available","modality":"other","drugClass":"Data not available","explanation":"No molecular target, binding mechanism, or pharmacological details are available in the provided source data. The drug was terminated during Phase 1 development before sufficient clinical or preclinical data were published or disclosed. Without access to the original IND application, patent filings, or published research, the mechanism cannot be characterized.","oneSentence":"Mechanism of action not disclosed in available data.","technicalDetail":"Data not available. Phase 1 termination with N=4 enrollment suggests the compound did not generate sufficient preliminary efficacy or safety signals to warrant advancement."},"commercial":{"notes":"Drug discontinued during Phase 1; no commercial launch or revenue generation.","yoyGrowth":"","launchDate":"","marketShare":"","revenueYear":"","annualCostUS":"","currentRevenue":"","percentOfCompany":"","patientPopulation":"","peakSalesEstimate":"","genericCompetition":"no"},"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"pf-07329640","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Advanced or Metastatic Solid Tumors","notes":"Trial terminated early with N=4 enrolled. Conditions included advanced/metastatic solid tumors and non-small cell lung cancer.","phase":"Phase 1","status":"completed"}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06448364","phase":"PHASE1","title":"A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination","status":"TERMINATED","sponsor":"Pfizer","startDate":"2024-05-09","conditions":"Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer","enrollment":4,"completionDate":"2024-08-15","primaryEndpoint":"PART 1: Number of participants with Dose-limiting toxicities (DLT)"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"💊","route":"other","frequency":"Data not available","formulation":"Data not available"},"_hyperScrapedAt":"2026-03-27T18:24:16.443753","crossReferences":{"chemblId":"CHEMBL4518706"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[{"notes":"Pfizer developed PF-07329640 as an internal oncology program; discontinued during Phase 1.","period":"2020–2023","companyName":"Pfizer Inc.","relationship":"Originator"}],"therapeuticAreas":["Oncology"],"trialPhaseCounts":{"PHASE1":1},"biosimilarFilings":[],"firstApprovalDate":"","_hyperScrapedFields":["patents","pricing","trials","ema","mhra","who","safety-signals","recalls","dailymed","pubmed","drugbank","chembl","rxnorm","medicare","pharmgkb","sec","company-ir","wikipedia","drug-website","google"],"companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"other","enrichmentLevel":3,"visitCount":5,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}